|
1. |
Pharmacologic Studies of Intra-Hepatic Artery Chemotherapy with Degradable Starch Microspheres |
|
Cancer Drug Delivery,
Volume 3,
Issue 1,
1986,
Page 1-14
CRAIG E. PFEIFLE,
STEPHEN B. HOWELL,
WILLIAM L. ASHBURN,
ROBERT M. BARONE,
JOSEPH J. BOOKSTEIN,
Preview
|
PDF (1095KB)
|
|
摘要:
The effect of degradable starch microspheres (DSM) on the pharmacokinetics of 4 drugs administered via the hepatic artery was studied in 5 patients with colon carcinoma metastatic to the liver. The 4 drugs were 99m-technitium diethylenetriamine pentaacetic acid (99mTc-DTPA), an agent which is not metabolized in the liver, and floxuridine, doxorubicin, and mitomycin, agents which undergo hepatic metabolism to varying extents. DSM transiently decreased arterial blood flow to normal liver an average of 64% and to hepatic tumor an average of 78%. DSM increased tumor exposure to DTPA by a mean of 1.71-fold, and increased hepatic exposure by 1.46-fold, but did not affect total plasma exposure. In contrast, DSM did reduce total plasma exposure to floxuridine by a mean of 34%, and to mitomycin by 20%. No information was available on the effect of DSM on plasma doxorubicin levels which never exceeded the limits of detection. Variation in the injection rate of DSM did not appear to influence the relative advantages produced in tumor or plasma AUCs. The estimated increase in tumor exposure produced by DSM was 3.8-fold for floxuridine, and 3.0-fold for mitomycin. These results reflect the differences in extent of hepatic metabolism of these agents, and agree closely with predictions made from mathematical models. Although DSM improved the therapeutic index, the increase in tumor exposure was insufficient to produce significant tumor regression.
ISSN:0732-9482
DOI:10.1089/cdd.1986.3.1
年代:1986
数据来源: MAL
|
2. |
Direct Effects of the Hypoxic Cell Sensitizer Misonidazole on Colony Formation in a Human Tumor Cloning Assay |
|
Cancer Drug Delivery,
Volume 3,
Issue 1,
1986,
Page 15-24
WERNER SCHEITHAUER,
DANIEL D. VON HOFF,
BARBARA FORSETH,
JOHN D. COWAN,
Preview
|
PDF (874KB)
|
|
摘要:
The human tumor cloning assay as described by Hamburger and Salmon was utilized to study the direct antitumor effects of the hypoxic cell sensitizer misonidazole (MISO). Cells from 106 tumor specimens directly obtained from patients were exposed to MISO at clinically achievable drug concentrations (0.5 mM). Of 30 evaluable tumors, seven specimens (23%) showed a ≤50% decrease of TCFU's. In vitro sensitivity to MISO was noted in human breast cancer, renal cancer, non small-cell lung cancer, and adenocarcinoma of unknown primary site. A dose response relationship was demonstrated in a subset of experiments including 6 patient's tumors and one human breast cancer cell-line. An analysis relating MISO sensitivity or resistance to the results obtained with other, simultaneously tested standard anticancer drugs indicated that tumors exhibiting a ≤50% decrease of TCFU's in the presence of MISO were also likely to be sensitive to other cytotoxic drugs. In summary, our data suggest that the 'nitroimidazoles' may exert clinically significant direct antitumor effects in individual tumors. The human tumor cloning assay may have potential to evaluate these direct effects of MISO-analogues and other new radiosensitizers currently being tested in clinical tri
ISSN:0732-9482
DOI:10.1089/cdd.1986.3.15
年代:1986
数据来源: MAL
|
3. |
131-I Coupled to Monoclonal Antibodies as Therapeutic Agents for Neuroectodermally Derived Tumors: Fact or Fiction? |
|
Cancer Drug Delivery,
Volume 3,
Issue 1,
1986,
Page 25-43
J.T. KEMSHEAD,
D.H. JONES,
L. LASHFORD,
J. PRICHARD,
I. GORDON,
F. BREATNACH,
H.B. COAKHAM,
Preview
|
PDF (6394KB)
|
|
摘要:
It has been suggested that monoclonal antibodies may be useful in targeting eytotoxie compounds to tumor cells. We have explored their use in targeting 131-I to highly radiosensitive primitive neural tumors such as neuroblastoma and pineoblastomas. Two routes of administration have been employed, intravenous and intrathecal. Our current experience in using radiolabelled antibodies is described, indicating toxicities seen and any therapeutic benefit observed. The results of the study suggest that if targeted radiation has a role in the treatment of these malignancies, it will be restricted to the eradication of small tumor masses from the body.
ISSN:0732-9482
DOI:10.1089/cdd.1986.3.25
年代:1986
数据来源: MAL
|
4. |
Abstracts from the First International Congress on Neo-Adjuvant Chemotherapy |
|
Cancer Drug Delivery,
Volume 3,
Issue 1,
1986,
Page 45-91
Preview
|
PDF (6635KB)
|
|
ISSN:0732-9482
DOI:10.1089/cdd.1986.3.45
年代:1986
数据来源: MAL
|
|